Standard PA criteria across payers typically include: Confirmed diagnosis of primary hyperlipidemia or HeFH or HoFH with supporting ICD-10 code Documented LDL-C level above payer-specified threshold (commonly 70 mg/dL or 100 mg/dL depending on cardiovascular risk category) Evidence of maximally tolerated statin therapy or documented statin intolerance Prescribing clinician is a cardiologist, lipidologist, or relevant specialist (some plans require specialist involvement) Previous trial of other LDL-lowering therapies (PCSK9 inhibitors or ezetimibe, plan-specific) Maintaining thorough PA documentation in secure patient records is essential for both initial approvals and denial appeals
Join us as we unravel the story behind semaglutide, examining its potential to redefine the landscape of weight loss management and provide new hope for those seeking effective and sustainable solutions to their weight loss journey
instead they are a precaution stemming from findings in the Saxenda (liraglutide) trials where a small number of participants reported psychiatric symptoms (though these were not significantly different from the placebo group)
The most common side effects are gastrointestinal nausea, mild vomiting, constipation, and diarrhea and are most common during the early titration phase
Typically, these medications are available only with prior authorization (PA) and must be prescribed as part of a chronic weightmanagement program, not for cosmetic or short-term use
increasing the potential for falsified versions (Jan 29, 2024)
/assets/images/provider/photos/2775905.jpeg)
